Prevalence of high-risk human papillomavirus infection (HPV) and correlation with postmenopausal hormonal therapy in Thai women aged more than 45 years old

Journal of the Medical Association of Thailand

Volumn 93, Issue 1, 2010, Pages 9-16

  Boonyanurak, Pongrak ^a   Panichakul, Suthee ^a   Wilawan, Kittisak ^a  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

High risk HPV; High risk human papillomavirus; Hormone therapy; Postmenopausal; Prevalence

Indexed keywords

ESTROGEN; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREVALENCE; RNA PROBE; THAILAND; VIRUS INFECTION; WART VIRUS;

AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DNA, VIRAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POSTMENOPAUSE; PREVALENCE; RISK; THAILAND;

EID: 77249130822     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Pengsaa P, Jindawijak S. Cervix uteri. In: Sriplung H, Sontipong S, Martin N, Wiangnon S, Vootiprux V, Cheirsilpa A, et al, editors. Cancer in Thailand. Vol. III, 1995-1997. Bangkok: Medical Publisher; 2003: 49-50.
2. Ferley J, Bray F, Pisani P, Parkin DM. Globocan 2002: Cancer incidence, mortality and prevalence worldwide, version 1.0. LARC Cancer base No. 5. Lyon: IARC Press; 2001.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
4. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1796-807.
5. Smith EM, Ritchie JM, Levy BT, Zhang W, Wang D, Haugen TH, et al. Prevalence and persistence of human papillomavirus in postmenopausal age women. Cancer Detect Prev 2003; 27: 472-80.
6. Giuliano AR, Papenfuss MR, Denman CA, de Zapien JG, Abrahamsen M, Hunter JB. Human papillomavirus prevalence at the USA-Mexico border among women 40 years of age and older. Int J STD AIDS 2005; 16: 247-51.
7. Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M, Franceschi S, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002; 87: 324-33.
8. Negrini BP, Schiffman MH, Kurman RJ, Barnes W, Lannom L, Malley K, et al. Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix. Cancer Res 1990; 50: 4670-5.
9. Brinton LA. Oral contraceptives and cervical neoplasia. Contraception 1991; 43: 581-95.
10. Beby-Defaux A, Bourgoin A, Ragot S, Battandier D, Lemasson JM, Renaud O, et al. Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security. J Med Virol 2004; 73: 262-8.
11. Kutza J, Smith E, Levy B, Jian J, Haugen T, Turek L. Use of hormone replacement therapy (HRT) and detection of human papillomavirus (HPV) DNA in postmenopausal women. Ann Epidemiol 2000; 10: 465-6.
12. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer 1994; 69: 167-71.
13. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677-84.
14. Halfon P, Trepo E, Antoniotti G, Bernot C, Cart-Lamy P, Khiri H, et al. Prospective evaluation of the hybrid capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance. J Clin Microbiol 2007; 45: 313-6.
15. Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, Opasatian O, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003; 187: 1246-56.
16. Ishida WS, Singto Y, Kanjanavirojkul N, Chatchawan U, Yuenyao P, Settheetham D, et al. Co-risk factors for HPV infection in Northeastern Thai women with cervical carcinoma. Asian Pac J Cancer Prev 2004; 5: 383-6.
17. Kanjanavirojkul N, Pairojkul C, Yuenyao P, Patarapadungkit N. Risk factors and histological outcome of abnormal cervix with human papilloma infection in northeastern Thai-women. Asian Pac J Cancer Prev 2006; 7: 567-70.
18. Smith EM, Levy BT, Ritchie JM, Jia J, Wang D, Haugen TH, et al. Is use of hormone replacement therapy associated with increased detection of human papillomavirus and potential risk of HPV-related genital cancers? Eur J Cancer Prev 2002; 11: 295-305.
19. Smith EM, Levy BT, Ritchie JM, Jia J, Wang D, Haugen TH, et al. Is use of hormone replacement therapy associated with increased detection of human papillomavirus and potential risk of HPV-related genital cancers? Eur J Cancer Prev 2002; 11: 295-305.
20. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 593-600.
21. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
22. Kedzia W, Gozdzicka-Jozefiak A, Kwasniewska A, Schmidt M, Miturski R, Spaczynski M. Relationship between HPV infection of the cervix and blood serum levels of steroid hormones among pre- and postmenopausal women. Eur J Gynaecol Oncol 2000; 21: 177-9.